Keep pulling the thread on Athos Therapeutics.
According to Mike Nally, FDA Commissioner Macri believes the current ability to model human biology is insufficient to justify smaller or less rigorous clinical trials for drug approvals.
Mike Nally predicts that within the next five years, the trend of rising drug development costs, known as Eroom's Law, will reverse and begin a downward trajectory for the first time in 50 years.
Athos Therapeutics utilized AI to identify novel biological targets for inflammatory bowel diseases that the speaker believes would have been undiscoverable by human scientists.
Dimitrios Iliopoulos asserts that the FDA currently lacks the necessary AI expertise outside of its oncology division to create an appropriate regulatory framework for AI-driven drug development.
The lead drug molecules currently in development pipelines were designed using AI models that predate modern generative AI like ChatGPT, obscuring the true state-of-the-art capabilities.
A tool with the widespread utility and accessibility of ChatGPT does not yet exist for scientists and clinicians in the drug development field.